ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 680 • 2014 ACR/ARHP Annual Meeting

    Influence of Antimalarial doesn´t Modify the Outcome of Cytopenias in Systemic Lupus Erythematosus

    Eugenia Enriquez Merayo1, Maria Galindo Izquierdo2, Esther Rodriguez-Almaraz3, Maria Martin Lopez2, Otto Martin Olivas Vergara4, Patricia E. Carreira5 and Isabel Mateo6, 1RHEUMATOLOGY, 12 DE OCTUBRE, MADRID, Spain, 2RHEUMATOLOGY, HOSPITAL 12 DE OCTUBRE, MADRID, Spain, 3Department of Rheumatology. Hospital Universitario 12 de Octubre, Madrid, Spain, 4HOSPITAL 12 DE OCTUBRE, MADRID, Spain, 5Rheumatology Department. Hospital Universitario 12 de Octubre, Madrid, Spain, 6Servicio De Reumatología, Hospital 12 De Octubre,, Madrid, Spain

    Background/Purpose: To analyze the effect of antimalarials (AM) as preventive factor for the development of severe cytopenias and in their outcome after treatment in a…
  • Abstract Number: 698 • 2014 ACR/ARHP Annual Meeting

    Grip Strength Identifies Increased Physical Disability in Women with Systemic Lupus Erythematosus

    James S. Andrews1, Mary Margaretten2, Jennifer Barton2, Jinoos Yazdany2, Ed Yelin2 and Patricia P. Katz3, 1Rheumatology, University of California San Francisco, San Francisco, CA, 2Medicine, University of California, San Francisco, San Francisco, CA, 3Medicine, University of California, San Francisco, CA

    Background/Purpose: Muscle weakness is common and contributes to physical disability in women with systemic lupus erythematosus (SLE). Recently, the Foundation for the National Institutes of…
  • Abstract Number: 699 • 2014 ACR/ARHP Annual Meeting

    Osteonecrosis in Systemic Lupus Erythematosus: Prevalence, Patterns and Outcomes

    Nimrit Dhillon1, Dominique Ibanez1, Dafna D. Gladman2 and Murray B. Urowitz2, 1Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 2University of Toronto, Toronto Western Hospital, Toronto, ON, Canada

    Background/Purpose: Osteonecrosis is a serious comorbidity of systemic lupus erythematosus (SLE).  The reported frequency of symptomatic osteonecrosis in SLE is variable, ranging from 4% to…
  • Abstract Number: 697 • 2014 ACR/ARHP Annual Meeting

    Venous and Arterial Thrombosis in SLE:  Differences in Natural History

    Katharine Hickman1, Laurence S. Magder2 and Michelle Petri3, 1University College London, London, United Kingdom, 2Department of Epidemiology and Public Health, University of Maryland, Baltimore, MD, 3Johns Hopkins University School of Medicine, Baltimore, MD

    Background/Purpose: Thrombosis is increased in SLE due to disease activity and co-morbid factors including antiphospholipid antibodies.  We separately investigated the natural history of venous vs.…
  • Abstract Number: 696 • 2014 ACR/ARHP Annual Meeting

    Clinical Characteristics and Outcome of Intestinal Pseudo-Obstruction in Patients with Systemic Lupus Erythematosus

    Lingling Zhang, Mengtao Li, Dong Xu, Na Gao, Li Zhang, Yong Hou, Qian Wang and Xiaofeng Zeng, Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China

    Background/Purpose: Intestinal pseudo-obstruction (IPO) is a rare clinical syndrome characterized by ineffective intestinal motility. IPO has been recently recognized as an uncommon complication of systemic…
  • Abstract Number: 695 • 2014 ACR/ARHP Annual Meeting

    Osteonecrosis in Patients with Systemic Lupus Erythematosus: Risk Factors and Clinical Outcome

    Andrea Zacarias1, Javier Narváez2, Sergi Heredia1, Helena Borrell1, Paula Estrada1, Alex Roset3, Nestor Arce Gonzalez3, Carmen Gomez Vaquero1, Olga Capdevila3 and Joan Miquel Nolla1, 1Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, 2Rheumatology, Hospital Universitario de Bellvitge. Barcelona. Spain, Barcelona, Spain, 3Internal Medicine, Hospital Universitario de Bellvitge, Barcelona, Spain

    Background/Purpose: To study the prevalence of osteonecrosis (ON) in patients with systemic lupus erythematosus (SLE) and to identify the risk factors for development of this…
  • Abstract Number: 694 • 2014 ACR/ARHP Annual Meeting

    Lupus Myocarditis: Clinical, Echocardiographic and Magnetic Resonance Characteristics

    Maria del Carmen Zamora Medina1, Hilda Fragoso-Loyo2, Martha Morelos3, Juan Jakez-Ocampo4, Luis Llorente5, Juan Rosas Saucedo6 and Yemil Atisha-Fregoso7, 1Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubiran, Mexico City, Mexico, 2Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico, Mexico, 3Radiology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, México, Mexico, 4Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, México, Mexico, 5Immunology and Rheumatology Department, Instituto Nacional de Ciencias Medicas y Nutricion, Mexico City, Mexico, 6Internal Medicine, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, México, Mexico, 7Internal Medicine, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico

    Background/Purpose Myocarditis is an uncommon manifestation with important morbidity and mortality in patients with Systemic Lupus Erythematosus (SLE). There are scant information about this manifestation…
  • Abstract Number: 693 • 2014 ACR/ARHP Annual Meeting

    Acute Myocarditis in Patients with Systemic Lupus Erythematosus: Experience from Affiliated Hospitals of Catholic University of Korea

    In-Woon Baek1, Ki-Jo Kim2, Yune-Jung Park3, Chong-Hyeun Yoon4, Wan-Uk Kim5 and Chul-Soo Cho1, 1Internal Medicine, Yeouido St. Mary's Hospital, The Catholic University of Korea, Seoul, South Korea, 2Internal Medicine, St. Vincent’s Hospital, The Catholic University of Korea, Suwon, South Korea, 3Internal Medicine, St. Vincent's Hospital, The Catholic University of Korea, Suwon, South Korea, 4Internal Medicine, Uijeongbu St. Mary's Hospital, The Catholic University of Korea, Uijeongbu, South Korea, 5Internal Medicine, Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul, South Korea

    Background/Purpose: To determine the factors associated with occurrence of acute myocarditis (AMC) and its outcomes in patients with systemic lupus erythematosus (SLE).  Methods: This was…
  • Abstract Number: 692 • 2014 ACR/ARHP Annual Meeting

    Circulating Anti-Ro/SSA Antibodies Are Associated with the Presence of Severe Mitral Regurgitation in Systemic Lupus Erythematosus

    Violeta Higuera1,2, Claudia Hübbe3 and Luis M. Amezcua-Guerra4, 1Juan Badiano #1 Col. Secion XV, Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City, Mexico, 2Rheumatology, Instituto Nacional de Cardiologia Ignacio Chavez, Mexico city, Mexico, 3Rheumatology, Instituto Nacional de Cardiología, Mexico City, Mexico, 4Mexican Board of Rheumatology, Mexico City, Mexico

    Background/Purpose: Systemic lupus erythematosus (SLE) is a complex autoimmune disorder involving multiple organ systems. The frequency of symptomatic heart disease ranges from 5 to 10%,…
  • Abstract Number: 691 • 2014 ACR/ARHP Annual Meeting

    Prevalence of Subclinical Echocardiographic Abnormalities in Patients with Systemic Lupus Erythematosus (SLE)

    Sergi Heredia1, Javier Narváez2, Andrea Zacarias1, Eulalia Armengol1, Gloria Albert1, Alex Roset3, Patricia Siguenza3, Xavier Juanola4, Manel Rubio Rivas3 and Joan Miquel Nolla1, 1Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, 2Rheumatology, Hospital Universitario de Bellvitge. Barcelona. Spain, Barcelona, Spain, 3Internal Medicine, Hospital Universitario de Bellvitge, Barcelona, Spain, 4Rheumatology, University Hospital Bellvitge, Barcelona, Spain

    Background/Purpose: To determine the prevalence of unsuspected echocardiographic abnormalities (excluding pericardial effusion) and to identify associated clinical and laboratory features in a large SLE cohort.…
  • Abstract Number: 689 • 2014 ACR/ARHP Annual Meeting

    Prednisone, Disease Activity and Hypertension Independently Predict Cataracts in Systemic Lupus Erythematosus (SLE)

    Khaled Alderaan1, Vuk Sekicki2, Laurence S. Magder3 and Michelle Petri4, 1King Fahad Specilaist Hospital, Dammam, Saudi Arabia, 2Medicine, Saint Agnes Hospital, Baltimore, MD, 3Department of Epidemiology and Public Health, University of Maryland, Baltimore, MD, 4Johns Hopkins University School of Medicine, Baltimore, MD

    Background/Purpose: Cataract is the most common ocular damage in SLE.  It is the second most frequent item in the SLICC/ACR Damage Index.  Apart from cumulative…
  • Abstract Number: 690 • 2014 ACR/ARHP Annual Meeting

    Lupus Patients Requiring First Corticosteroid Intervention Late in Disease Course – a Phenotypic Description

    Barry J. Sheane1, Dominique Ibanez2, Dafna D. Gladman3 and Murray B. Urowitz3, 1Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 2Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 3University of Toronto, Toronto Western Hospital, Toronto, ON, Canada

    Background/Purpose The University of Toronto Lupus Clinic (UTLC) recently described the phenotype of a group of inception patients with SLE who remained naïve of corticosteroid…
  • Abstract Number: 688 • 2014 ACR/ARHP Annual Meeting

    Corticosteroids in Early Treatment Pathways in SLE

    John G. Hanly1, Amyn Sayani2, Steve Doucette3, Sandra Iczkovitz2 and Jorge Alfonso Ross2, 1Division of Rheumatology, Dalhousie University and Capital Health, Halifax, NS, Canada, 2Medical Affairs, GlaxoSmithKline, Mississauga, ON, Canada, 3Dalhousie University and Capital Health, Halifax, NS, Canada

    Background/Purpose: The treatment algorithm for patients with new onset systemic lupus erythematosus (SLE) is more variable than that for other rheumatic diseases (e.g. rheumatoid arthritis).…
  • Abstract Number: 687 • 2014 ACR/ARHP Annual Meeting

    Effect of Corticosteroid Use By Dose on the Risk of Developing Organ Damage over Time in Systemic Lupus Erythematosus—the Hopkins Lupus Cohort

    Sarah Al Sawah1, Xiang Zhang1, Baojin Zhu1, Laurence S. Magder2, Shonda A Foster1, Noriko Iikuni1 and Michelle Petri3, 1Eli Lilly and Company, Indianapolis, IN, 2Department of Epidemiology and Public Health, University of Maryland, Baltimore, MD, 3Johns Hopkins University School of Medicine, Baltimore, MD

    Background/Purpose:  Reduction of corticosteroid dose remains an important goal in the management of systemic lupus erythematosus (SLE). Current standard of care in SLE relies heavily…
  • Abstract Number: 685 • 2014 ACR/ARHP Annual Meeting

    Successful Withdrawal and Discontinuation of Immunosuppressants in Lupus Patients: Outcomes and Predictors

    Zahi Touma1, Murray B. Urowitz2, Dominique Ibanez1 and Dafna D. Gladman2, 1Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 2University of Toronto, Toronto Western Hospital, Toronto, ON, Canada

    Background/Purpose:   Physicians and patients (Pts) are hesitant to withdraw immunosuppressant (IS) in Pts in clinical remission as the consequences of this approach are unknown.…
  • « Previous Page
  • 1
  • …
  • 2185
  • 2186
  • 2187
  • 2188
  • 2189
  • …
  • 2607
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology